Lexaria Bioscience (LEXX) Revenue (2017 - 2026)

Lexaria Bioscience has disclosed Revenue across 10 years of filings, most recently posting $20000.0 for Q1 2026.

• In Q1 2026, Revenue fell 88.51% year-over-year to $20000.0; the TTM figure through May 2026 stood at $194000.0 (down 68.5% YoY), while the FY2025 annual figure was $705923.0, up 52.05% from the prior year.
• Revenue came in at $20000.0 for Q1 2026 at Lexaria Bioscience, down from $174000.0 in the prior quarter.
• In the past five years, Revenue ranged from a high of $183923.0 in Q4 2024 to a low of $20000.0 in Q1 2026.
• Average Revenue over 5 years is $103620.4, with a median of $98726.0 recorded in 2022.
• Year-over-year, Revenue surged 624.09% in 2024 and tumbled 88.51% in 2026.
• Over 5 years, Revenue stood at $97735.0 in 2022, then jumped by 54.78% to $151278.0 in 2023, then advanced by 21.58% to $183923.0 in 2024, then decreased by 5.4% to $174000.0 in 2025, then plunged by 88.51% to $20000.0 in 2026.
• Per Business Quant data, the three most recent Revenue figures were $20000.0 in Q1 2026, $174000.0 in Q3 2025, and $174000.0 in Q2 2025.